News

Credit union adopts digital piggy bank benefit for student loan repayment

A latte costs $4.50 — round it up to $5 even and that extra 50 cents can help employees pay off their student debt years sooner. UMassFive College Federal Credit Union is experimenting with such a benefit. The credit union's new student loan repayment benefit uses change from employees’ personal purchases to pay down the interest of student loans. Read more >>
Read more...

BrandVerge Appoints Former NBCUniversal Executive Scott Schiller to Advisory Board; Unveils Latest Product Features

BrandVerge, a premium advertising marketplace for media buyers and sellers, today announced the appointment of Scott Schiller, Digital Media Executive, formerly of NBCUniversal, to its all-star Advisory Board. The company is celebrating a successful first year in business, experiencing 30 percent month-over-month growth, adding 257 active accounts to its platform. Read more >>
Read more...

Rapid Lyme disease test may be available in late 2020

The drawn-out process for diagnosing Lyme disease could become a thing of the past – good news for the thousands of people each year who get the tick-borne illness. A new detection test created by Ionica Sciences – located at Cornell’s McGovern Center life sciences incubator – has been sparked by a FuzeHub grant to begin moving from the laboratory bench into approvals, production and doctors’ offices. Read more >>
Read more...

Myomo Announces Technology Licensing Program for International Markets

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has launched a business development program to bring its proprietary MyoPro orthotic product line to a greater number of country markets outside of the United States. Read more >>
Read more...

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company under which such company will develop and commercialize antibody-based products targeting a tumor-associated carbohydrate antigen (TACA) identified by Siamab’s proprietary TACA discovery platform. Read more >>
Read more...